CLINICAL RESEARCH: PULMONARY HYPERTENSION
Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan
Robyn J. Barst, MD*,1,*,
David Langleben, MD ,1,
David Badesch, MD ,1,
Adaani Frost, MD ,1,
E. Clinton Lawrence, MD||,1,
Shelley Shapiro, MD¶,1,
Robert Naeije, MD#,1,
Nazzareno Galie, MD**,1 on behalf of the STRIDE-2 Study Group
* Department of Pediatrics, Columbia University Medical Center, New York, New York
Jewish General Hospital, Montreal, Quebec, Canada
University of Colorado, Denver, Colorado
Baylor College of Medicine, Houston, Texas
|| McKelvey Lung Transplantation Center, Emory University, Atlanta, Georgia
¶ University of Southern California, Los Angeles, California
# Erasmus University, Brussels, Belgium
** Institute of Cardiology, University of Bologna, Bologna, Italy.
Manuscript received September 20, 2005;
revised manuscript received December 23, 2005,
accepted January 9, 2006.
* Reprint requests and correspondence: Dr. Robyn J. Barst, Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2-255, New York, New York 10032. (Email: rjb3{at}columbia.edu).
OBJECTIVES: We sought to determine the optimal dose of the selective endothelin A (ETA) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included.
BACKGROUND: Endothelin is a mediator of PAH. In a preliminary PAH study, the selective ETA receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization (WHO) functional class (FC), and hemodynamics.
METHODS: In this double-blind, placebo-controlled 18-week study, 247 PAH patients (idiopathic, or associated with connective tissue disease or congenital heart disease) were randomized; 245 patients were treated: placebo (n = 62), sitaxsentan 50 mg (n = 62) or 100 mg (n = 61), or OL (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind) bosentan (n = 60). The primary end point was change in 6MW distance from baseline to week 18. Secondary end points included change in WHO FC, time to clinical worsening, and change in Borg dyspnea score.
RESULTS: At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compared with the placebo group (31.4 m, p = 0.03), and an improved WHO FC (p = 0.04). The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p = 0.07) and for OL bosentan, 29.5 m (p = 0.05). The incidence of elevated hepatic transaminases (>3x the upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.
CONCLUSIONS: Treatment with the selective ETA receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.
|
Abbreviations and Acronyms
| | ALT = alanine aminotransferase | | ANCOVA = analysis of covariance | | AST = aspartate aminotransferase | | DSMB = Data Safety Monitoring Board | | ET = endothelin | | FC = functional class | | INR = international normalized ratio | | ITT = intent-to-treat | | OL = open label | | PAH = pulmonary arterial hypertension | | 6MW = six-min walk | | STRIDE = Sitaxsentan To Relieve ImpaireD Exercise study | | ULN = upper limit of normal | | WHO = World Health Organization |
|
This article has been cited by other articles:
|
|
|
|
 
Y.-L. Lin, Y.-C. Wu, C.-S. Gau, and M.-S. Lin
Value of preapproval safety data in predicting postapproval hepatic safety and assessing the legitimacy of class warning
Therapeutic Advances in Drug Safety,
February 1, 2012;
3(1):
13 - 24.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. B. Gabler, B. French, B. L. Strom, Z. Liu, H. I. Palevsky, D. B. Taichman, S. M. Kawut, and S. D. Halpern
Race and Sex Differences in Response to Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension
Chest,
January 1, 2012;
141(1):
20 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Raja and S. M. Raja
Treating pulmonary arterial hypertension: current treatments and future prospects
Therapeutic Advances in Chronic Disease,
November 1, 2011;
2(6):
359 - 370.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Weber, M. Silver, D. Cromer, S. Kaminski, T. Wirick, and J. Vallejo
Under Pressure: Pulmonary Arterial Hypertension . . . A Mother's Struggle
Crit. Care Nurse,
August 1, 2011;
31(4):
87 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Soon, C. M. Treacy, M. R. Toshner, R. MacKenzie-Ross, V. Manglam, M. Busbridge, M. Sinclair-McGarvie, J. Arnold, K. K. Sheares, N. W. Morrell, et al.
Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension
Thorax,
April 1, 2011;
66(4):
326 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Barst, S. I. Ertel, M. Beghetti, and D. D. Ivy
Pulmonary arterial hypertension: a comparison between children and adults
Eur. Respir. J.,
March 1, 2011;
37(3):
665 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gomberg-Maitland, C. Dufton, R. J. Oudiz, and R. L. Benza
Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?: A Clinical Perspective
J. Am. Coll. Cardiol.,
March 1, 2011;
57(9):
1053 - 1061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-T. N. Lee, N. Kirkham, M. K. Johnson, J. L. Lordan, A. J. Fisher, and A. J. Peacock
Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension
Eur. Respir. J.,
February 1, 2011;
37(2):
472 - 474.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sitbon and N. Galie
Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals
Eur. Respir. Rev.,
December 1, 2010;
19(118):
272 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Vachiery and G. Simonneau
Management of severe pulmonary arterial hypertension
Eur. Respir. Rev.,
December 1, 2010;
19(118):
279 - 287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Cordina and D. S. Celermajer
Therapeutic approaches in adults with congenital heart disease-associated pulmonary arterial hypertension
Eur. Respir. Rev.,
December 1, 2010;
19(118):
300 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. F. Berger and D. Bonnet
Treatment options for paediatric pulmonary arterial hypertension
Eur. Respir. Rev.,
December 1, 2010;
19(118):
321 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Valerio, C. E. Handler, P. Kabunga, C. J. Smith, C. P. Denton, and J. G. Coghlan
Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension
Rheumatology,
November 1, 2010;
49(11):
2147 - 2153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Degano, O. Sitbon, L. Savale, G. Garcia, D. S. O'Callaghan, X. Jais, M. Humbert, and G. Simonneau
Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis
Chest,
June 1, 2010;
137(6):
1297 - 1303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Archer, E. K. Weir, and M. R. Wilkins
Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies
Circulation,
May 11, 2010;
121(18):
2045 - 2066.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Iversen, A. S. Jensen, T. V. Jensen, N. G. Vejlstrup, and L. Sondergaard
Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial
Eur. Heart J.,
May 1, 2010;
31(9):
1124 - 1131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Toole, J. S. Ikonomidis, W. Y. Szeto, J. L. Zellner, J. Mulcahy, R. L. Deardorff, and F. G. Spinale
Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics
J. Thorac. Cardiovasc. Surg.,
March 1, 2010;
139(3):
646 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Badesch, G. E. Raskob, C. G. Elliott, A. M. Krichman, H. W. Farber, A. E. Frost, R. J. Barst, R. L. Benza, T. G. Liou, M. Turner, et al.
Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry
Chest,
February 1, 2010;
137(2):
376 - 387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J-L Vachiery and A. Davenport
The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
Eur. Respir. Rev.,
December 1, 2009;
18(114):
260 - 271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Henno, C. Maurey, C. Danel, P. Bonnette, R. Souilamas, M. Stern, C. Delclaux, M. Levy, and D. Israel-Biet
Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-{kappa}B and endothelin-1
Eur. Respir. J.,
December 1, 2009;
34(6):
1329 - 1337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Task Force for the Diagnosis and Treatment of, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension
Eur. Respir. J.,
December 1, 2009;
34(6):
1219 - 1263.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Oudiz, N. Galie, H. Olschewski, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al.
Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
November 17, 2009;
54(21):
1971 - 1981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Eur. Heart J.,
October 2, 2009;
30(20):
2493 - 2537.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Hoeper
Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?
Eur. Respir. J.,
September 1, 2009;
34(3):
529 - 530.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Peacock, R. Naeije, N. Galie, and L. Rubin
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Eur. Respir. J.,
July 1, 2009;
34(1):
231 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. SCHOINDRE, C. MEUNE, A. T. DINH-XUAN, J. AVOUAC, A. KAHAN, and Y. ALLANORE
Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis
J Rheumatol,
July 1, 2009;
36(7):
1481 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al.
Diagnosis and Assessment of Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1_Suppl_S):
S55 - S66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Barst, J. S. R. Gibbs, H. A. Ghofrani, M. M. Hoeper, V. V. McLaughlin, L. J. Rubin, O. Sitbon, V. F. Tapson, and N. Galie
Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1_Suppl_S):
S78 - S84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al.
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1_Suppl_S):
S97 - S107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Galie, B. H. Brundage, H. A. Ghofrani, R. J. Oudiz, G. Simonneau, Z. Safdar, S. Shapiro, R. J. White, M. Chan, A. Beardsworth, et al.
Tadalafil Therapy for Pulmonary Arterial Hypertension
Circulation,
June 9, 2009;
119(22):
2894 - 2903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. McLaughlin, M. Humbert, G. Coghlan, P. Nash, and V. Steen
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis
Rheumatology,
June 1, 2009;
48(suppl_3):
iii25 - iii31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O Kowal-Bielecka, R Landewe, J Avouac, S Chwiesko, I Miniati, L Czirjak, P Clements, C Denton, D Farge, K Fligelstone, et al.
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
Ann Rheum Dis,
May 1, 2009;
68(5):
620 - 628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Pesaturo, P. N. Johnson, and E. Z. Ramsey
Pediatric Pulmonary Hypertension: A Pharmacotherapeutic Review
Journal of Pharmacy Practice,
April 1, 2009;
22(2):
166 - 178.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Souza and C. Jardim
Trends in pulmonary arterial hypertension
Eur. Respir. Rev.,
March 1, 2009;
18(111):
7 - 12.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Galie, A. Manes, L. Negro, M. Palazzini, M. L. Bacchi-Reggiani, and A. Branzi
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
Eur. Heart J.,
February 2, 2009;
30(4):
394 - 403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Zaca, M. Metra, R. Danesi, C. Lombardi, G. Verzura, and L. Dei Cas
Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade
Therapeutic Advances in Respiratory Disease,
February 1, 2009;
3(1):
11 - 14.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. D. McGoon, A. E. Frost, R. J. Oudiz, D. B. Badesch, N. Galie, H. Olschewski, V. V. McLaughlin, M. J. Gerber, C. Dufton, D. J. Despain, et al.
Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
Chest,
January 1, 2009;
135(1):
122 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. X. Kleber, T. Bollmann, M. M. Borst, A. Costard-Jackle, R. Ewert, M. Kivikko, T. Petterson, P. Pohjanjousi, S. Sonntag, and G. Wikstrom
Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study
J. Clin. Pharmacol.,
January 1, 2009;
49(1):
109 - 115.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Galie and A. Manes
CHAPTER 24 Pulmonary Hypertension
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. R. Henkens, C. T.-J. Gan, S. A. van Wolferen, M. Hew, A. Boonstra, J. W. R. Twisk, O. Kamp, E. E. van der Wall, M. J. Schalij, A. Vonk Noordegraaf, et al.
ECG Monitoring of Treatment Response in Pulmonary Arterial Hypertension Patients
Chest,
December 1, 2008;
134(6):
1250 - 1257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L Hrometz and K. M Shields
Role of Ambrisentan in the Management of Pulmonary Hypertension
Ann. Pharmacother.,
November 1, 2008;
42(11):
1653 - 1659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Benza, R. J. Barst, N. Galie, A. Frost, R. E. Girgis, K. B. Highland, C. Strange, C. M. Black, D. B. Badesch, L. Rubin, et al.
Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension: A 1-Year, Prospective, Open-Label Observation of Outcome and Survival
Chest,
October 1, 2008;
134(4):
775 - 782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Eur. Heart J.,
August 2, 2008;
29(16):
1936 - 1948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert
Review: Therapeutic advances in pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease,
August 1, 2008;
2(4):
249 - 265.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Frey, W. Muck, S. Unger, U. Artmeier-Brandt, G. Weimann, and G. Wensing
Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers
J. Clin. Pharmacol.,
August 1, 2008;
48(8):
926 - 934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al.
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Circulation,
June 10, 2008;
117(23):
3010 - 3019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Avouac, J Wipff, A Kahan, and Y Allanore
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials
Ann Rheum Dis,
June 1, 2008;
67(6):
808 - 814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Wrishko, J. Dingemanse, A. Yu, C. Darstein, D. L. Phillips, and M. I. Mitchell
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects
J. Clin. Pharmacol.,
May 1, 2008;
48(5):
610 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Chin and L. J. Rubin
Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
April 22, 2008;
51(16):
1527 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Heart,
March 1, 2008;
94(Suppl_1):
i1 - i41.
[Full Text]
[PDF]
|
|
|
|
|
|
|
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Thorax,
March 1, 2008;
63(Suppl_2):
ii1 - ii41.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dupuis and M. M. Hoeper
Endothelin receptor antagonists in pulmonary arterial hypertension
Eur. Respir. J.,
February 1, 2008;
31(2):
407 - 415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Kamezaki, H. Tasaki, K. Yamashita, M. Tsutsui, S. Koide, S. Nakata, A. Tanimoto, M. Okazaki, Y. Sasaguri, T. Adachi, et al.
Gene Transfer of Extracellular Superoxide Dismutase Ameliorates Pulmonary Hypertension in Rats
Am. J. Respir. Crit. Care Med.,
January 15, 2008;
177(2):
219 - 226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E Girgis, A. E Frost, N. S Hill, E. M Horn, D. Langleben, V. V McLaughlin, R. J Oudiz, I. M Robbins, J. R Seibold, S. Shapiro, et al.
Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
Ann Rheum Dis,
November 1, 2007;
66(11):
1467 - 1472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Chest,
September 1, 2007;
132(3):
998 - 1006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr
Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials
Chest,
September 1, 2007;
132(3):
764 - 772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin
Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines
Chest,
June 1, 2007;
131(6):
1917 - 1928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Benedict
Sitaxsentan in the management of pulmonary arterial hypertension
Am. J. Health Syst. Pharm.,
February 15, 2007;
64(4):
363 - 368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T Wittbrodt and A. Abubakar
Sitaxsentan for Treatment of Pulmonary Hypertension
Ann. Pharmacother.,
January 1, 2007;
41(1):
100 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gomberg-Maitland
Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better?
Eur. Respir. J.,
October 1, 2006;
28(4):
683 - 686.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Distler and A. Pignone
Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment
Rheumatology,
October 1, 2006;
45(suppl_4):
iv22 - iv25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Riemekasten and C. Sunderkotter
Vasoactive therapies in systemic sclerosis
Rheumatology,
October 1, 2006;
45(suppl_3):
iii49 - iii51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Rubin
Endothelin-1 and the Pulmonary Vascular Response to Altitude: A New Therapeutic Target?
Circulation,
September 26, 2006;
114(13):
1350 - 1351.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin and M. D. McGoon
Pulmonary Arterial Hypertension
Circulation,
September 26, 2006;
114(13):
1417 - 1431.
[Full Text]
[PDF]
|
|
|
|
